References
- Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991: 324(26): 1865–75
- Stults BM, Dere WH, Caine TH. Long-term anticoagulation: indications and management. West J Med 1989: 151(4): 414–29
- Wolf PA, Dawber TR, Thomas HE Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978: 28(10): 973–7
- Petersen P, Madsen EB, Brun B, et al. Silent cerebral infarction in chronic atrial fibrillation. Stroke 1987: 18(6): 1098–100
- Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989: 1(8631): 175–9
- Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. N Engl J Med 1990: 322(12): 863–8
- The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990: 323(22): 1505–11
- Bern MM, Lokich JJ, Wallach SR, et al. Very low doses of warfarin can prevent thrombosis in central venous catheters: a randomized prospective trial. Ann Intern Med 1990: 112(6): 423–8
- Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990: 323(3): 147–52
- Meade TW. Low-dose warfarin and low-dose aspirin in the primary prevention of ischemic heart disease. Am J Cardiol 1990: 65(6): 7–11C
- Falk RH. A plea for a clinical trial of anticoagulation in dilated cardiomyopathy. Am J Cardiol 1990: 65(13): 914–5
- Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990: 322(18): 1260–4
- Rooke TW, Osmundson PJ. Heparin and the in-hospital management of deep venous thrombosis: cost considerations. Mayo Clin Proc 1986: 61 (3): 198–204
- Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest 1986: 89(2 Suppl): 16–25S
- Biemer JJ. Control of oral anticoagulant therapy. Ann Clin Lab Sci 1988: 18(6): 421–8
- Poller L, Hirsh J. Special report: a simple system for the derivation of International Normalized Ratios for the reporting of prothrombin time results with North American thromboplastin reagents. Am J Clin Pathol 1989: 92(1): 124–6
- Hirsh J, Poller L, Deykin D, et al. Optimal therapeutic range for oral anticoagulants. Chest 1989: 95(2 Suppl): 5–11S [erratum, Chest 1989: 96(4): 962]
- Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982: 307(27): 1676–81
- Saour JN, Sieck JO, Mamo LA, et al. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990: 322(7): 428–32
- Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989: 87(2): 144–52
- Cole MS, Minifee PK, Wolma FJ. Coumarin necrosis: a review of the literature. Surgery 1988: 103(3): 271–7
- Hyman BT, Landas SK, Ashman RF, et al. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987: 82(6): 1233–7
- Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989: 87(2): 153–9
- Wilcox CM, Truss CD. Gastrointestinal bleeding in patients receiving long-term anticoagulant therapy. Am J Med 1988: 84(4): 683–90